What is ubrogepant and how is it used for the acute treatment of migraine attacks?

What is Ubrogepant?

Ubrogepant (Ubrelvy®) is an oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist FDA-approved for the acute treatment of migraine attacks with or without aura in adults. 1

Mechanism of Action

• Ubrogepant works by selectively blocking CGRP receptors, which play a central role in migraine pathophysiology, without causing vasoconstriction—making it safe for patients with cardiovascular disease, uncontrolled hypertension, or cerebrovascular disease where triptans are contraindicated. 2, 3

Position in Migraine Treatment Algorithm

• Ubrogepant is recommended as a third-line option for moderate-to-severe acute episodic migraine in adults who do not tolerate or have inadequate response to combination therapy of a triptan plus an NSAID or acetaminophen. 2
• First-line treatment should be an NSAID (ibuprofen 400–800 mg, naproxen 500–825 mg) or acetaminophen 1000 mg for mild-to-moderate attacks. 2
• If inadequate response after 2–3 episodes, add a triptan (sumatriptan 50–100 mg, rizatriptan 10 mg) to the NSAID. 2
• Only after failure of triptan-NSAID combinations should CGRP antagonists like ubrogepant be considered. 2

Dosing and Administration

• Available doses: 50 mg and 100 mg tablets. 1
• Initial dose: Take one tablet (50 mg or 100 mg) at migraine onset, with or without food. 1
• Second dose: Most patients can take a second tablet 2 hours after the first dose if needed, but do not take a second dose within 24 hours if consuming grapefruit/grapefruit juice or taking moderate CYP3A4 inhibitors (verapamil, cyclosporine, ciprofloxacin, fluconazole, fluvoxamine). 1
• Maximum frequency: Limit ubrogepant use to no more than 8 migraine attacks per 30-day period to prevent medication-overuse headache, and initiate preventive therapy if acute treatment is needed more than twice weekly. 2

Efficacy Data

• At 2 hours post-dose, pain freedom was achieved in 19.2–21.8% of ubrogepant-treated patients versus 11.8–14.3% with placebo (number-needed-to-treat [NNT] = 11–12). 4, 5, 6
• At 2 hours post-dose, absence of the most bothersome symptom (photophobia, phonophobia, or nausea) occurred in 37.7–38.9% of ubrogepant patients versus 27.4–27.8% with placebo. 4, 5
• Sustained pain freedom from 2–24 hours was achieved in 12.7–15.4% of ubrogepant patients versus 8.2–8.6% with placebo. 4
• Ubrogepant is most effective when taken early in the attack while pain is still mild. 3, 7

Safety Profile

• Most common adverse events (within 48 hours): nausea (1.8–4.1%), somnolence (0.4–2.1%), dry mouth (0.4–2.1%), and dizziness (1.4–2.1%). 4, 5, 8
• Adverse events were generally mild and transient, with no serious treatment-related adverse events or discontinuations due to adverse events reported in pivotal trials. 8
• No cardiovascular risk: Unlike triptans, ubrogepant does not cause vasoconstriction and is safe for patients with ischemic heart disease, uncontrolled hypertension, or cerebrovascular disease. 2, 3

Contraindications

• Absolute contraindication: Concurrent use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole). 1
• Allergy: Do not use if allergic to ubrogepant or any ingredients. 1

Drug Interactions

• Moderate CYP3A4 inhibitors (verapamil, cyclosporine, ciprofloxacin, fluconazole, fluvoxamine): Do not take a second dose within 24 hours if using these medications. 1
• Strong CYP3A4 inducers (phenytoin, barbiturates, rifampin, St. John's Wort): May reduce ubrogepant efficacy; dose adjustment may be needed. 1
• Grapefruit juice: Avoid taking a second dose within 24 hours if consuming grapefruit or grapefruit juice. 1

Special Populations

• Pregnancy: Unknown if ubrogepant harms the fetus; a pregnancy registry exists (1-833-277-0206 or empresspregnancyregistry.com). 1
• Breastfeeding: Unknown if ubrogepant passes into breast milk; discuss with healthcare provider. 1
• Liver or kidney problems: Inform healthcare provider before use. 1
• Pediatric use: Safety and efficacy not established in children. 1

Critical Medication-Overuse Prevention

• Limit all acute migraine medications—including ubrogepant—to ≤2 days per week (≤10 days per month) to avoid medication-overuse headache, which can paradoxically increase headache frequency and lead to daily headaches. 2, 3
• If a patient requires acute treatment more than twice weekly, initiate preventive therapy immediately rather than increasing acute medication frequency. 2, 3

Comparison to Other Acute Treatments

• NNT for pain freedom at 2 hours: Ubrogepant (12) is comparable to NSAIDs like naproxen (11) and acetaminophen (12), but less effective than triptans (NNT = 3.5 for sumatriptan + NSAID combination). 2, 6
• Advantages over triptans: No vasoconstriction, safe in cardiovascular disease, minimal medication-overuse headache risk. 2, 3
• Disadvantages versus triptans: Lower efficacy, higher cost, reserved for triptan failures or contraindications. 2

Emerging Evidence

• Prodromal treatment: Recent data suggest ubrogepant 100 mg taken during the migraine prodrome (before headache onset) may prevent moderate-to-severe headache and resolve prodromal symptoms (photophobia, fatigue, neck pain, phonophobia) as early as 1–2 hours post-dose. 9, 10

Medications to Avoid

• Opioids (hydrocodone, oxycodone, morphine, codeine, tramadol) and butalbital-containing compounds are absolutely contraindicated for migraine because they have questionable efficacy, high dependence risk, and precipitate rebound headaches. 2, 3